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a b s t r a c t
Schizophrenia is a serious mental disorder with lifelong morbidity and increased mortality. Currently, the
diagnosis of the disorder is based on patient history and clinical examination, but it has a low inter-rater
reliability and validity. Various biological variables, such as event related potentials, hormonal levels,
brain ventricular volume and hippocampal size, have been put forth as objective markers to diagnose
schizophrenia, but none with the desired sensitivity and specificity. It has been shown that microRNAs
play a vital role in gene regulation in schizophrenia and have been proposed as possible biomarkers
for the disease. When compared to the free microRNAs in the body fluids, exosomal microRNAs are more
resistant to degradation and are easier to isolate. There are no studies reporting exosomal microRNAs as
biomarkers for schizophrenia, but we hypothesize that exosomal microRNAs will be found to be potential
biomarkers for diagnosis, prognosis assessment and medication response to patients with this disease.
 2017 Elsevier Ltd. All rights reserved.
Introduction
Schizophrenia
Schizophrenia is a chronic, debilitating mental disorder affect-
ing about 1% of the general population worldwide [1,2]. This con-
dition is characterized by positive symptoms (hallucinations and
delusions), negative symptoms (social withdrawal and apathy)
and cognitive symptoms [3]. Also, it is a heterogeneous disorder
with unknown etiology. Multiple factors such as genetic risks
and environmental factors, like childhood trauma and social disad-
vantages, have been implicated as risk factors for the disease [4,5].
It has been found that the genetic component is a significant risk
factor for schizophrenia, with heritability ranging from 30 to 80%
depending on the degree of family relationship with the proband
[6,7]. Genome wide association studies have identified various
genetic loci for schizophrenia, but the effect size has not been
found to be causal. It has been suggested to be a disorder of mul-
tiple genes with a small effect size [8]. Along with this, epigenetic
and environmental interactions with the genes have a significant
role in the pathogenesis of schizophrenia [9,10].
The diagnosis of schizophrenia is based on clinical symptoms,
relying mainly on self-reports from patients and mental state
examination. This method of diagnosing the disorder lacks objec-
tivity and may lead to misdiagnosis and discrepancy between the
clinicians [11]. This advocates for the generation of biomarkers
based on physical and biological tests for diagnosis, prognosis
assessment and treatment response in patients with schizophrenia
[12].
MicroRNA
MicroRNAs (miRNA) are a class of small RNAs that are single-
stranded and contain 21–23 nucleotides [13]. They are non-
coding and do not translate into any proteins, but have a role in
the regulation of MessengerRNA (mRNA) [14,15]. The miRNA inac-
tivates mRNA by binding with the 30 – UTR region and can lead to
either degradation of mRNA or blocking the translation of mRNA
[16]. Thus, miRNA has an active role in the gene expression and
it is found that single miRNA can regulate multiple gene expres-
sions. Various biological functions have been attributed to miRNAs
such as cell proliferation, differentiation, migration and apoptosis
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[17]. It has been suggested that nearly 70% of miRNA are present in
the central nervous system (CNS) and have an important role in the
pathogenesis of various CNS disorders [18]. Various studies have
suggested the potential role of miRNAs as a biomarker for various
diseases like cancer and neurological disorders, including psychi-
atric disorders such as schizophrenia [19]. MiRNAs have potential
as diagnostic, prognostic, and treatment response biomarkers [20].
Exosomes
Exosomes are small vesicles of approximately 50–100 nm in
diameter and have a lipid bilayer [21]. They can be distinguished
from other microvesicles released from the cells by their size, den-
sity, lipid composition of the bilayer and specific protein markers,
such as Alix protein [22,23]. Exosomes are released from almost
every type of cell in the body, which includes lymphocytes, cardiac,
epithelial, muscle and neural cells, and are released into the extra-
cellular fluid. Detection is possible using different body fluids like
CSF, serum, saliva and urine [24]. These small vesicles are formed
either inside the cells by the fusion of multivesicular bodies
(MVBs) with the plasma membrane or directly from the plasma
membrane [25]. The release of exosomes can be found in both
physiological and pathological conditions. Exosomal cargos repre-
sent the cell of its origin and can act as a liquid biopsy, especially
in cancer detection [26]. Hence, exosomes and their cargo can act
as potential biomarkers for physiological and pathological condi-
tions [27].
The hypothesis
Hypothesizing exosomal miRNAs in schizophrenia are potential
biomarkers
MiRNAs have been shown to be potential biomarkers in various
neurodegenerative and psychiatric disorders, such as Alzheimer’s
dementia, Parkinson’s disease and schizophrenia [28,29]. These
miRNAs are present in various body fluids, like CSF, serum, saliva
and urine. They can be detected in body fluids in free form and
embedded within exosomes. When compared to free miRNA, those
present within exosomes are more resistant to degradation and
accumulate in larger quantities, which are easier to detect [30].
The exosomal miRNAs could be involved in schizophrenia patho-
physiology and the unique signature of miRNAs present in the exo-
somes could be used for diagnosis and prognosis assessments [31].
Hence, we hypothesize that exosomal miRNAs are better targets as
potential biomarkers than free miRNAs in schizophrenia and could
be used for various aspects like diagnosis of the disorder, assess-
ment of severity and prognosis, treatment response to medications
and personalized treatment options.
Evaluation of the hypothesis
MicroRNA (miRNA) and schizophrenia
Animal models of schizophrenia and miRNA
22q11 deletion syndrome (22q11DS), also known as DiGeorge
syndrome, is a disorder with one of the strongest genetic risks
for schizophrenia [32,33]. Nearly 30% of individuals with this dis-
order develop schizophrenia in adolescence or early adulthood.
The primary pathology in this condition is the hemizygous deletion
of a 1.5–3 Mb region of chromosome 22 [34]. In a study that
utilized a mouse model of DiGeorge syndrome, there was
haplo-insufficiency of Dgcr8, a miRNA biogenesis gene, in the
disordered genetic region leading to the depletion of miR-25 and
miR-185. These two miRNAs are important for the regulation of
the sarcoplasmic reticulum Ca2 – ATPase (SERCA2) protein. In their
absence, there is an overexpression of SERCA2, leading to increased
long-term potentiation (LTP). Similarly, it is shown that patients
with schizophrenia have elevated levels of SERCA2 in their brain
[35]. This study has highlighted the importance of miRNA in the
pathogenesis of schizophrenia.
In another similar study, defects in the Dgcr8 mediated miRNAs
have led to functional flaws in Chemokine receptor 4/Chemokine
ligand 12 (Cxcr4/Cxcl12). It is found that Cxcr4/Cxcl12 is important
for the migration of interneurons, and their defect in DiGeorge syn-
drome leads to defects in the migration of cortical interneurons
and hippocampal dentate precursor cells. This explains the neu-
rodevelopmental model of schizophrenia and it is observed that
the expression of CXCL12 is decreased in the olfactory neurons of
patients with schizophrenia [36]. This study shows that miRNA
has a role in the migration of neurons during the CNS development
and supports the neurodevelopmental model of schizophrenia.
In a comparative study, the cyclic AMP-responsive elements
binding- and NMDA regulated miRNA miR-132 is downregulated
in patients with schizophrenia when compared to normal controls
and patients with bipolar disorder. It is also observed that admin-
istration of NMDA antagonist to adult mice results in the down
regulation of miR-132 in the mice prefrontal cortex [37]. Another
miRNA, miR-137, which is important in the glucocorticoid
receptor-dependent signaling, has been found to be down regu-
lated in mouse model of schizophrenia [38].
Clinical studies of schizophrenia and miRNA
Dysregulation of miRNA in schizophrenia has recently received
more attention, which is evident from the increasing number of
articles published every year. Many studies have supported the
notion that miRNAs are not only important in the normal develop-
ment of the human brain, but also play a vital role in the pathogen-
esis of various CNS disorders. In a study by Beveridge and Cairns,
the authors reviewed miRNAs associated with schizophrenia [39].
It was hypothesized that miRNA could be the possible unifying link
for different aspects of schizophrenia, such as neurodevelopmental
nature of the disorder, neurotransmitter abnormalities and varied
treatment response to different antipsychotic medications.
In another study, Perkins et al., the researchers compared
miRNA from the prefrontal cortex of patients with schizophrenia
and normal controls. It was found that the expression of 15 miR-
NAs decreased and the expression of one increased in the
schizophrenia group when compared to the controls [40]. This
shows that the differential expression of miRNAs leads to altered
gene regulation and molecular abnormalities seen in schizophre-
nia. For example, miR – 195 is involved in the regulation signaling
pathways and is implicated in the development of schizophrenia
[41].
Glutamate receptor ionotropic d1 (GRID1) gene is implicated in
the susceptibility of schizophrenia. The intron region of this gene
also encodes for miR – 346. In one study, the expression levels of
miR – 346 were found to be lower in patients with schizophrenia
when compared to normal controls [42]. Several other studies have
reported the involvement of miRNAs in schizophrenia pathology
and as circulating biomarkers (Table 1).
MiRNA biomarkers for early onset of schizophrenia
Early diagnosis of schizophrenia is very critical for predicting
the overall outcome of the disease. We performed a network anal-
ysis on protein molecules implicated in early onset schizophrenia
using ingenuity pathway analysis tool (Qiagen Inc) to identify
whether miRNAs implicated in advance stage disease may play a
role in the disease onset. Our analysis showed that miRNA
biomarkers for late stage disease may be implicated in the regula-
tion of the proteins involved in early diseases onset. Specifically,
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miR-137, miR-34a and miR-21 were identified to target key pro-
teins implicated in schizophrenia development and progression
(Fig. 1). This suggests that miRNAs may be useful in identifying
the disease at an early stage of schizophrenia.
Exosomes and schizophrenia
Clinical studies on schizophrenia and exosomes
In the central nervous system, neurons and glial cells release
exosomes. The content of the exosomes varies depending on the
disorder and on its different phases/severity. This identification is
also important to understand the disease’s pathophysiology and
help in the development of new treatment methods. Since exo-
somes carry signature contents related to the disorder, they are
currently considered as potential biomarkers.
In the case of schizophrenia, very few studies have explored the
role of exosomes and their contents in the pathophysiology of this
illness. In one study, differential expression of miR-497 from the
pre-cortex exosomes has been identified in schizophrenia and
bipolar disorders [55]. Hence, it is important to further study the
content of exosomes, proteins and miRNA in schizophrenia as it
may throw light on the pathogenesis of the disease and lead to bet-
ter therapeutics.
Exosomal miRNAs as biomarkers in other disorders
Even though recent technologies, like next-generation deep
sequencing (NGS), have given the ability to analyze and profile free
miRNA from biological fluids like blood, the collection and isolation
of free miRNA from these fluids needs to be improved. Moreover,
the ribonuclease present in the blood can act on the free extracel-
lular miRNA and lead to degradation. These factors have important
impacts on the usage of free extracellular miRNA as biomarkers, as
they reduce the sensitivity and specificity. In one study, the
authors compared miRNA derived from cell-free plasma or serum
and exosomes, and found that the exosomal miRNA is protected
from RNaseA treatment [30]. This study has highlighted that exo-
somes provide a consistent source of miRNA for disease biomarker
detection when compared to free extracellular miRNA.
Currently, the diagnosis of Alzheimer’s disease is based on cog-
nitive functions, neuroimaging and biochemical analysis of body
fluids. In a recent review, authors reviewed the literature on exoso-
mal miRNAs as biomarkers for Alzheimer’s disease and concluded
that molecular contents of the exosomes, proteins and miRNAs
hold promise as novel biomarkers [56].
Many studies have shown that the exosomes in cancer cells play
a role in the cell-cell communication important for survival and
metastasis of tumor. Also, the expression of miRNAs is dysregu-
lated in cancer cells and this differential expression can be used
as biomarkers. In one study, exosomal miRNA as a cancer biomar-
ker is analyzed. It is found that even though exosomes are a stable
source of miRNA for biomarker detection, current methods of exo-
some isolation and miRNA quantification are questioned [57].
Other studies have reviewed the role of exosomal miRNAs as
biomarkers for disease detection in cardiovascular disorders and
infectious diseases. These studies highlight the potential of exoso-
mal miRNAs as biomarkers [58–60].
Consequence of the hypothesis
The hypothesis highlights the importance of studying the exo-
somal miRNAs. We intend to explore this hypothesis by novel
methods incorporating cell and animal models of schizophrenia
and comparing pre-clinical results with clinical studies.
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Table 1
MicroRNAs implicated in schizophrenia pathology and biomarker.
S. No MicroRNA Role Tissue Genes targeted References
1. miR-137 Pathology/Biomarker Blood/PBMCs EFNB2 Wu et al. [43],
Mahmoudi and
Cairns [44]
2. miR-181b, miR-219-2-3p, miR-
195, miR-1308 and let-7 g
Biomarker Blood/serum Not identified Shi et al. [45]
3. miR-30e, miR-181b, miR-34a,
miR-346, and miR-7
Biomarker PBMCs Not identified Sun et al. [46]
4. miR 9-5p, miR29a-3p, miR106b-
5p, miR125a-3p and miR125b-3p.
Biomarker Blood Not Identified Camkurt et al. [47]
5. miR-21 Biomarker Blood Not Identified Chen et al. [48]
6. miR-34a, miR-449a, miR-564,
miR-432, miR-548d, miR-572 and
miR-652
Biomarker Blood Not Identified Lai et al. [49]
7. miR-206 SNP in gene NT5C2 alters binding of miR-206
thereby affecting its regulation
Cell Culture NT5C2 Hauberg et al. [50]
8. miR-214 Targets quaking gene and regulates dendritic
morphogenesis
Mouse
Hippocampal
Neurons
Quaking (Qki) Irie et al. [51]
9. miR-9 Down regulated in neural progenitor cells
(NPC) in Schizophrenia patients
Human NPC Several genes and proteins
dysregulated after miR-9 over
expression.
Topol et al. [52]
10. miR-219 Upregulated in Nural stem cells (NSC) in
Schizophrenia patients and inhibits their
proliferation.
Human NSC NLX (NSC nuclear receptor) Murai et al. [53]
11. miR-7 Plasma Shank3 Zhang et al. [54]
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